Pilar Ortega-Rivera

Oxford Road
Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Olive Oil and the Impact of Gastrointestinal Adverse Events During Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: A Post-hoc Analysis of the MADIET Trial.

Olive Oil and the Impact of Gastrointestinal Adverse Events During Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: A Post-hoc Analysis of the MADIET Trial.

Journal: Archivos de bronconeumologia

Published: January 20, 2026

TeloNet is born: why all specialities need to be aware of telomere biology disorders.

TeloNet is born: why all specialities need to be aware of telomere biology disorders.

Journal: Frontiers in medicine

Published: January 03, 2026

Challenging the status quo for therapeutic clinical trials in fibrotic interstitial lung diseases.

Challenging the status quo for therapeutic clinical trials in fibrotic interstitial lung diseases.

Journal: Thorax

Published: December 07, 2025

Interstitial lung disease fatigue and breathlessness (ILD-FAB) programme: a multidisciplinary feasibility study.

Interstitial lung disease fatigue and breathlessness (ILD-FAB) programme: a multidisciplinary feasibility study.

Journal: BMJ open respiratory research

Published: August 12, 2025

The benefits of a rapid diagnostic primary care circuit for interstitial lung disease.

The benefits of a rapid diagnostic primary care circuit for interstitial lung disease.

Journal: NPJ primary care respiratory medicine

Published: July 27, 2025

A statistical model for lung function trajectory and mortality in patients with fibrotic interstitial lung disease.

A statistical model for lung function trajectory and mortality in patients with fibrotic interstitial lung disease.

Journal: American journal of respiratory and critical care medicine

Published: May 14, 2025

Residual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury.

Residual lung abnormality following COVID-19 hospitalisation is characterised by biomarkers of epithelial injury.

Journal: EBioMedicine

Published: September 17, 2024

The interstitial lung disease patient pathway: from referral to diagnosis.

The interstitial lung disease patient pathway: from referral to diagnosis.

Journal: ERJ open research

Published: September 05, 2024

The respiratory microbiome in patients with post-COVID-19 residual lung abnormalities resembles that of healthy individuals and is distinct from idiopathic pulmonary fibrosis.

The respiratory microbiome in patients with post-COVID-19 residual lung abnormalities resembles that of healthy individuals and is distinct from idiopathic pulmonary fibrosis.

Journal: ERJ open research

Published: August 17, 2024

Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with "idiopathic" interstitial lung disease.

Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with "idiopathic" interstitial lung disease.

Journal: Clinical immunology (Orlando, Fla.)

Published: January 17, 2024

Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases.

Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases.

Journal: Thorax

Published: November 02, 2023

Assessing the Burden and Prognostic Value of Cough in Idiopathic Pulmonary Fibrosis.

Assessing the Burden and Prognostic Value of Cough in Idiopathic Pulmonary Fibrosis.

Journal: Annals of the American Thoracic Society

Published: September 01, 2023

Showing 1-12 of 33

Last Updated: 09/26/2026